OBJECTIVES: Recent studies suggest that a proportion of ovarian tumors may actually originate in the distal fallopian tube. The objective of this study was to examine the relationship between dominance (a surrogate for site of origin) and survival, following a diagnosis of epithelial ovarian cancer. METHODS: We classified 1,386 tumors as dominant (putatively originating in the ovary) and non-dominant (putatively originating in the fallopian tube), using parameters obtained from pathology reports. Dominant tumors were restricted to one ovary or one involved ovary that exceeded the other in dimension by at least twofold, while non-dominant tumors were identified as having a greater likelihood of a tubal origin if the disease was equally distributed across the ovaries. Cox proportional hazards models were used to estimate the hazard ratios (HRs) and 95% confidence intervals (CIs) associated with dominance. RESULTS: Non-dominant tumors were more likely to be serous, stage III/IV, and be associated with a BRCA1/2 mutation, increasing parity and use of estrogen hormone replacement therapy (p ≤ 0.01). In contrast, 46 and 26% of the dominant tumors were serous and endometrioid, respectively, with a more even distribution of stage (p < 0.0001). Women with a non-dominant tumor had an increased risk of death compared to women with a dominant tumor (multivariate HR 1.28; 95% CI 1.02-1.60). Findings were similar in our analysis restricted to serous only subtypes (HR 1.28; 95% CI 1.01-1.63). CONCLUSION: These preliminary findings suggest significantly worse survival among women diagnosed with a tumor putatively arising from fallopian tube.
OBJECTIVES: Recent studies suggest that a proportion of ovarian tumors may actually originate in the distal fallopian tube. The objective of this study was to examine the relationship between dominance (a surrogate for site of origin) and survival, following a diagnosis of epithelial ovarian cancer. METHODS: We classified 1,386 tumors as dominant (putatively originating in the ovary) and non-dominant (putatively originating in the fallopian tube), using parameters obtained from pathology reports. Dominant tumors were restricted to one ovary or one involved ovary that exceeded the other in dimension by at least twofold, while non-dominant tumors were identified as having a greater likelihood of a tubal origin if the disease was equally distributed across the ovaries. Cox proportional hazards models were used to estimate the hazard ratios (HRs) and 95% confidence intervals (CIs) associated with dominance. RESULTS:Non-dominant tumors were more likely to be serous, stage III/IV, and be associated with a BRCA1/2 mutation, increasing parity and use of estrogen hormone replacement therapy (p ≤ 0.01). In contrast, 46 and 26% of the dominant tumors were serous and endometrioid, respectively, with a more even distribution of stage (p < 0.0001). Women with a non-dominant tumor had an increased risk of death compared to women with a dominant tumor (multivariate HR 1.28; 95% CI 1.02-1.60). Findings were similar in our analysis restricted to serous only subtypes (HR 1.28; 95% CI 1.01-1.63). CONCLUSION: These preliminary findings suggest significantly worse survival among women diagnosed with a tumor putatively arising from fallopian tube.
Authors: Clare J Reade; Sarah Finlayson; Jessica McAlpine; Alicia A Tone; Michael Fung-Kee-Fung; Sarah E Ferguson Journal: J Obstet Gynaecol Can Date: 2013-07
Authors: Robert A Soslow; Guangming Han; Kay J Park; Karuna Garg; Narciso Olvera; David R Spriggs; Noah D Kauff; Douglas A Levine Journal: Mod Pathol Date: 2011-12-23 Impact factor: 7.842
Authors: G Hofstetter; N Concin; I Braicu; R Chekerov; J Sehouli; I Cadron; T Van Gorp; F Trillsch; S Mahner; H Ulmer; C Grimm; D Cacsire Castillo-Tong; R Zeillinger; A G Zeimet; I Vergote Journal: Gynecol Oncol Date: 2013-07-20 Impact factor: 5.482
Authors: Tianyi Huang; Mary K Townsend; Nicolas Wentzensen; Britton Trabert; Emily White; Alan A Arslan; Elisabete Weiderpass; Julie E Buring; Tess V Clendenen; Graham G Giles; I-Min Lee; Roger L Milne; N Charlotte Onland-Moret; Ulrike Peters; Dale P Sandler; Leo J Schouten; Piet A van den Brandt; Alicja Wolk; Anne Zeleniuch-Jacquotte; Shelley S Tworoger Journal: Cancer Epidemiol Biomarkers Prev Date: 2019-11-12 Impact factor: 4.254